Danese S, Kamble P, Yang J, Le Moine JG, Khan S, Hawe E, Agboton C, Wang S, Irving PM. Systematic literature review and meta-analysis: real-world mucosal healing in Vedolizumab-treated patients with Crohn's disease. GastroHep. 2022 Feb 16. doi: 10.1155/2022/6975416
Mollo A, Hernandez M, Marsal JR, Esquerda A, Rius F, Blanco-Vaca F, Verdaguer J, Pozzilli P, de Leiva A, Mauricio D, Action LADA 8. Latent autoimmune diabetes in adults is perched between type 1 and type 2: evidence from adults in one region of Spain. Diabetes Metab Res Rev. 2013 Sep;29(6):446-51. doi: 10.1002/dmrr.2411
Du XL, Parikh RC, Lairson DR, Giordano SH, Cen P. Comparative effectiveness of platinum-based chemotherapy versus taxane and other regimens for ovarian cancer. Med Oncol. 2013 Mar;30(1):440. doi: 10.1007/s12032-012-0440-4
Codony-Servat J, Garcia-Albeniz X, Pericay C, Alonso V, Escudero P, Fernandez-Martos C, Gallego R, Martinez-Cardus A, Martinez-Balibrea E, Maurel J. Soluble FAS in the prediction of benefit from cetuximab and irinotecan for patients with advanced colorectal cancer. Med Oncol. 2013 Mar;30(1):428. doi: 10.1007/s12032-012-0428-0
Earnshaw SR, Wilson M, Joshi AV. The effect of recombinant activated factor VII in the treatment of intracerebral hemorrhage on health plan budgets. Managed Care Interface. 2007 Jan 1;19(11):39-45.
Earnshaw SR, Wilson MR, Joshi AV. Health plan budget impact analysis of recombinant activated factor VII (rFVIIa) in the treatment of intracerebral hemorrhage. Managed Care Interface. 2006;19(11):39-45.
Earnshaw SR, Candrilli SD, Fernandes AW, Higashi MK. A cost-effectiveness analysis of antibiotic therapy in macrolide-resistant community-acquired pneumonia. Managed Care Interface. 2005 Oct 1;18(10):36-44.